TY - JOUR
T1 - 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure
T2 - A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
AU - Heidenreich, Paul A.
AU - Bozkurt, Biykem
AU - Aguilar, David
AU - Allen, Larry A.
AU - Byun, Joni J.
AU - Colvin, Monica M.
AU - Deswal, Anita
AU - Drazner, Mark H.
AU - Dunlay, Shannon M.
AU - Evers, Linda R.
AU - Fang, James C.
AU - Fedson, Savitri E.
AU - Fonarow, Gregg C.
AU - Hayek, Salim S.
AU - Hernandez, Adrian F.
AU - Khazanie, Prateeti
AU - Kittleson, Michelle M.
AU - Lee, Christopher S.
AU - Link, Mark S.
AU - Milano, Carmelo A.
AU - Nnacheta, Lorraine C.
AU - Sandhu, Alexander T.
AU - Stevenson, Lynne Warner
AU - Vardeny, Orly
AU - Vest, Amanda R.
AU - Yancy, Clyde W.
N1 - Publisher Copyright:
© 2022 American Heart Association, Inc., the American College of Cardiology Foundation, and the Heart Failure Society of America.
PY - 2022/5/3
Y1 - 2022/5/3
N2 - Aim: The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure” replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the “2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure.” The 2022 guideline is intended to provide patient-centric recommendations for clinicians to prevent, diagnose, and manage patients with heart failure. Methods: A comprehensive literature search was conducted from May 2020 to December 2020, encompassing studies, reviews, and other evidence conducted on human subjects that were published in English from MEDLINE (PubMed), EMBASE, the Cochrane Collaboration, the Agency for Healthcare Research and Quality, and other relevant databases. Additional relevant clinical trials and research studies, published through September 2021, were also considered. This guideline was harmonized with other American Heart Association/American College of Cardiology guidelines published through December 2021. Structure: Heart failure remains a leading cause of morbidity and mortality globally. The 2022 heart failure guideline provides recommendations based on contemporary evidence for the treatment of these patients. The recommendations present an evidence-based approach to managing patients with heart failure, with the intent to improve quality of care and align with patients’ interests. Many recommendations from the earlier heart failure guidelines have been updated with new evidence, and new recommendations have been created when supported by published data. Value statements are provided for certain treatments with high-quality published economic analyses.
AB - Aim: The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure” replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the “2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure.” The 2022 guideline is intended to provide patient-centric recommendations for clinicians to prevent, diagnose, and manage patients with heart failure. Methods: A comprehensive literature search was conducted from May 2020 to December 2020, encompassing studies, reviews, and other evidence conducted on human subjects that were published in English from MEDLINE (PubMed), EMBASE, the Cochrane Collaboration, the Agency for Healthcare Research and Quality, and other relevant databases. Additional relevant clinical trials and research studies, published through September 2021, were also considered. This guideline was harmonized with other American Heart Association/American College of Cardiology guidelines published through December 2021. Structure: Heart failure remains a leading cause of morbidity and mortality globally. The 2022 heart failure guideline provides recommendations based on contemporary evidence for the treatment of these patients. The recommendations present an evidence-based approach to managing patients with heart failure, with the intent to improve quality of care and align with patients’ interests. Many recommendations from the earlier heart failure guidelines have been updated with new evidence, and new recommendations have been created when supported by published data. Value statements are provided for certain treatments with high-quality published economic analyses.
KW - ACC/AHA Clinical Practice Guidelines
KW - ACE inhibitors
KW - acute decompensated heart failure
KW - angiotensin and neprilysin receptor antagonist
KW - angiotensin receptor antagonist
KW - atrial fibrillation
KW - beta blockers
KW - cardiac amyloidosis
KW - cardiac failure
KW - cardio-oncology
KW - cardiogenic shock
KW - cardiomyopathy
KW - cardiomyopathy in pregnancy
KW - chronic heart failure
KW - congestive heart failure
KW - diabetes
KW - guideline-directed medical therapy
KW - heart failure
KW - heart failure rehabilitation
KW - heart failure with mildly reduced ejection fraction
KW - heart failure with preserved ejection fraction
KW - heart failure with reduced ejection fraction
KW - mineralocorticoid receptor antagonists
KW - mitral regurgitation
KW - palliative care
KW - reduced ejection fraction
KW - right heart pressure
KW - sacubitril-valsartan
KW - SGLT2 inhibitors
KW - social determinants of health
KW - sodium glucose co-transporter 2
KW - systolic heart failure
KW - valvular heart disease
UR - http://www.scopus.com/inward/record.url?scp=85128629604&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85128629604&partnerID=8YFLogxK
U2 - 10.1016/j.jacc.2021.12.012
DO - 10.1016/j.jacc.2021.12.012
M3 - Article
C2 - 35363500
AN - SCOPUS:85128629604
SN - 0735-1097
VL - 79
SP - e263-e421
JO - Journal of the American College of Cardiology
JF - Journal of the American College of Cardiology
IS - 17
ER -